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Undiﬀerentiated endometrial sarcomas (UESs) of the ovary are very rare tumors. This paper presents a case of a 56-year-old
patient with a history of hysterectomy and bilateral salpingectomy seven years ago for uterine leiomyomata. Intraoperatively, a
tumor originating from the left ovary, adherent to the sigmoid colon, with inﬁltration of the small intestine and the vaginal
apex was found. Histologically, the tumor was composed of pleomorphic round and oval to spindled cells with polymorphous
vesicular nuclei with coarse chromatin and large nucleoli. Mitotic activity was brisk. There were large necrotic areas. Adjacent
to the tumor tissue endometrium-like glands surrounded by ﬁbrous stroma with macrophages corresponding to ovarian
endometriosis were noted. Tumor cells showed diﬀuse strong immunoreactivity for vimentin and patchy strong staining for
CD10; no reactivities were found for AE1/AE3, desmin, S-100, LCA, CD20, c-kit, and CD31. The patient died of her neoplastic
d i s e a s ef o u rm o n t h sp o s t o p e r a t i v e l y .C D 1 0i sf r e q u e n t l ye x p r e s s e di nd i ﬀerent gynecopathological as well as other lesions, and,
thus, nonspeciﬁc without relevance to the classiﬁcation of this case. Morphological features, extensive sampling, and appropriate
immunohistochemistry including markers for cytokeratins and myogenic diﬀerentiation are mandatory to arrive at the correct
diagnosis.
1.Introduction
Ovarian endometrioid stromal sarcomas (ESSs) are rare
tumors with about 50 cases reported in the literature. They
are composed of cells resembling the stromal cells of normal
proliferativeendometrium.Thesetumorsarereportedatany
age, but most of them occur in the ﬁfth and sixth decades. At
presentation, the symptoms are nonspeciﬁc and attributable
to the presence of a pelvic mass. At the time of operation,
most of ovarian ESS are high stage [1–6].
Previously, ESSs in general and in the ovary were catego-
rized in low and high grade tumors based on mitotic counts.
High grade ESS of the ovary accounted for 17% of cases only
in one study [4, 5]. However, the lack of speciﬁc evidence
of endometrial stromal cell origin in most cases of high-
grade tumors leads to the designation of undiﬀerentiated
endometrial sarcomas (UESs). These sarcomas are charac-
terized by marked cellular pleomorphism and brisk mitotic
activity and carry a very poor prognosis [7, 8]. CD10, the
common acute lymphoblastic lymphoma antigen (CALLA),
has been reported on as a marker for normal and neoplastic
endometrial stromal cells previously [9, 10]. Recently, the
diagnostic consideration of CD10 immunoexpression in
endometrial stromal neoplasms has changed signiﬁcantly
[7]. In this study we describe the clinicopathologic features
of a UES of the ovary with regard to recently published
literature and emphasis on a discussion of lacking relevance
of CD10 immunoreactivity in the diﬀerential diagnosis.2 Pathology Research International
2. Case Presentation
A 56-year-old patient presented with a tumor of the left
ovary, which was found during abdominal sonography. She
noted an increase of her abdomen associated with a feeling
of swelling. Her history was remarkable for hysterectomy
and bilateral salpingectomy seven years ago for uterine
leiomyomata. Gynecological examination showed a tumor
ﬁlling the pelvis minor. Computed tomography revealed a
12 × 9cm partially solid, partially cystic lesion of adnexal
origin; no enlarged lymph nodes were identiﬁed.
Intraoperatively, a tumor originating from the left ovary
and adherent to the sigmoid colon, the small intestine, and
the vaginal apex was found in the pelvis minor. The right
ovary was unremarkable. Tumor, vaginal apex, omentum
majus, a segment of the small intestine as well as right
ovary were removed; there were no ascites and no clinical
impression of residual tumor.
The tumor was submitted for frozen section exam-
ination, and a diagnosis of an undiﬀerentiated ovarian
neoplasia was given. The resected specimens were ﬁxed in
10% neutral buﬀered formaldehyde solution. The tumor
was surrounded by a smooth capsule, which showed broad
defects. The cut surface consisted of gray-yellowish friable
and partially necrobiotic tissues. Stainings were carried out
on sections of the paraﬃn-embedded tissue blocks cut
at 3µm. Besides hematoxylin and eosin staining (H&E),
a standard immunohistochemical testing was conducted
using a BenchMark series automated slide stainer (Ventana
Medical Systems) with commercially available antibodies
form DAKO (Carpinteria, CA) to the cytokeratin marker
AE1/AE3 (1:50), desmin (1:50), vimentin (prediluted,
rediluted at 1:5), MIB-1 (1:100), LCA (prediluted), S-
100 (1:200), CD20 (1:4) as well as prediluted ready-
to-use antibodies from Ventana to c-kit, synaptophysin,
estrogen- and progesterone receptor, CD31 and CD10.
Additionally, a reticulin-staining after G¨ om¨ ori was per-
formed.
Histologically, the tumor was composed of pleomor-
phic round and oval to spindled cells. Their nuclei were
polymorphous vesicular with coarse chromatin and large
nucleoli (Figure 1). The cytoplasmata were scant. More than
10 mitotic ﬁgures per 10 high power ﬁelds were readily
identiﬁed. Fibrous septa intersected the tumor nodules.
Geographically conﬂuent necrotic areas were abundant.
A network of interstitial thin walled blood vessels was
demonstrated by CD31 immunohistochemistry. Reticulin
ﬁbers surrounded single tumor cells. There were transitions
to areas with rather monotonous cells (Figure 2). Call-Exner
bodieswerenotidentiﬁed.Tumorcellsinﬁltratedtheovarian
capsule were demonstrated on its surface, and inﬁltrated
blood as well as lymphatic vessels. Adjacent to the tumor
tissue endometrium-like glands corresponding to ovarian
endometriosis were found, surrounded by broad ﬁbrous
stroma with macrophages; there was no condensation of
tumor cells around endometriotic glands “periglandular col-
laring” or polypoid intraluminal projections by the sarcoma
(Figure 3).
Figure 1: The high grade UES of the ovary is composed of
dediﬀerentiated round and oval to spindled cells. The nuclei are
polymorphous; vesicular with coarse chromatin and large nucleoli;
the cytoplasmata are scant. Mitotic ﬁgures are readily identiﬁed
(H&E, ×400).
Figure 2: Areas with smaller and more monotonous cells are
observed focally (H&E, ×400).
Figure 3: Endometrium-like glands corresponding to ovarian
endometriosis were surrounded by broad ﬁbrous stroma with
macrophages (×100).Pathology Research International 3
Figure 4: Tumor cells of high grade ovarian UES show focal strong
immunostaining for CD10 (×400).
Immunohistochemically, tumor cells showed diﬀuse
strong reactivity for vimentin and patchy strong staining
for CD10 in about 50% of cells (Figure 4); there was no
staining of tumor cells for AE1/AE3, desmin, S-100, LCA,
CD20, c-kit, and CD31. Estrogen and progesterone receptor
reactivities were noted focally in a small percentage of
neoplastic cells only. In some tumor areas, up to 60% of
tumor cells reacted for MIB-1. Endometriotic glands showed
abundant nuclear immunostaining for hormone receptors.
There was histological evidence of tumor inﬁltration in
the resected specimens of the vaginal apex and the segment
of the small intestine with microscopically positive margins
at the latter. The right ovary as well as the omentum
majus was free of tumor. The sections of the previous
hysterectomy specimen were reviewed; they showed benign
leiomyomata and discrete foci of adenomyosis without
architectural or cytological atypia, and there was no evidence
for sarcomatous changes.
Based on these ﬁndings the tumor was interpreted as
high-grade ESS or UES, respectively, of the ovary with
inﬁltration of the vaginal apex and the small intestine.
There was no postoperative adjuvant therapy. A second-
look laparotomy two months later was done due to a CT
scan showing an intestinal mass and revealed a conglomerate
tumorof10×10cm,involvingsmallandlargeintestine.This
tumor was biopsied only and was histologically identical to
the previously diagnosed UES. The patient was referred to
an oncological center for radiation therapy and died four
months postoperatively of her neoplastic disease.
3. Discussion withReview of the Literature
Thecommonacutelymphoblasticleukemiaantigen(CALLA
or CD10), a 90 to 110-kDa membrane-bound endopepti-
dase, is expressed on the cell surface of most cases of acute
lymphoblastic leukemia, other types of leukemia, as well
as lymphomas and nonhematopoietic neoplasms [11, 12].
This cell surface enzyme reduces cellular response to peptide
hormones by regulating local peptide concentration [11].
Thus, many hormone-sensitive and peptide-sensitive cells as
well as their corresponding neoplasms express CD10 antigen
[11], including normal endometrial stroma and ESS [9, 10].
Although CD10 has been considered a marker for ESS
[11], some studies have shown that many other uterine
neoplasms like uterine smooth muscle tumors, adenosarco-
mas, malignant M¨ ullerian mixed tumors, rhabdomyosarco-
mas, endometrial carcinomas, endocervical adenocarcino-
mas, uterine tumors resembling ovarian sex cord tumors,
perivascular round cell tumors, mesonephritic carcinomas,
and gestational trophoblastic disease may express CD10
[12]. In the ovary, Ordi and Romagosa [13]n o t e dav e r y
limited but strong CD10 positivity in ovarian stroma. In
contrast, Khin and Kikkawa [14] and Groisman and Meir
[15] detected no immunoreactivity for CD10 in stromal
cells of normal ovaries, suggesting that CD10 may help
in identifying subtle foci of endometriosis surrounding
M¨ ullerian-type glands as endometrial stroma stains for
CD10.However,OlivaandGarcia-Miralles[12]noticedfocal
CD10 expression in ovarian stroma being stronger in cases
with a background of stromal hyperthecosis or a presence
of corpora lutea questioning the use of CD10 when focally
present in stroma surrounding M¨ ullerian-type glands. There
is no evidence for CD10 expression in ovarian surface
epithelial cells or epithelial inclusions [13–15]. Nevertheless,
CD10 may be positive in serous and mucinous carcinomas
and Brenner tumors as well as the stroma surrounding
serous borderline tumors and serous, endometrioid, and
c l e a rc e l lc a r c i n o m a s[ 12–14]. Oliva et al. [12]r e p o r t e d
on CD10 expression in a large series of pure stromal and
sex cord-stromal tumors of the ovary. They observed that
frequency and intensity of CD10 immunoreactivity in these
tumors are low and contrast with the typical strong and
diﬀuse immunostaining in endometrial stromal tumors,
and concluded that CD10 should not be used in isolation
in the diﬀerential diagnosis, but should be interpreted in
the proper context, taking into consideration the patient’s
clinical history, the morphological appearance of the tumor,
and judicious use of immunohistochemical markers. As
another clue its nonspeciﬁcity CD10 immunoreactivity has
also been noted in uterine leiomyosarcomas [7, 16].
CD10 expression of UES of the ovary is not well charac-
terized. The previously published data are mainly available
on uterine high-grade ESS. In such tumors, McCluggage and
Sumathi [9] observed positive staining in four of six cases in
a usually focal pattern. In their study on M¨ ullerian system-
derived neoplastic mesenchymal cells Mikami and Hata [17]
notedmoderatestainingintensityinthesinglecaseofuterine
high-grade endometrial sarcoma.
Thereareseveralaspectsthatneedtobeconsideredinthe
diﬀerential diagnosis of the presented case. UES of the ovary
should be diagnosed only after excluding an undiﬀerentiated
carcinoma, malignant mixed M¨ u l l e r i a nt u m o ro rc a r c i -
nosarcoma, respectively, and high-grade myogenic sarcoma.
Therefore, extensive sampling to exclude skeletal or smooth
muscle diﬀerentiation or even small foci of carcinoma
is mandatory [7]. Recently, Soslow and Ali noted that
the immunophenotype of most M¨ ullerian adenosarcomas
resembled that of endometrial stromal tumors (positive for
estrogen and progesterone receptors, WT1, and CD10, with4 Pathology Research International
variable expression of smooth muscle markers, androgen
receptor and cytokeratin); sarcomatous overgrowth was
related to loss of expression of CD10 as well as estrogen and
progesterone receptors [18]. Since there was no evidence for
anexpressionofmyogenicmarkers(desmin)andcytokeratin
(AE1/AE3) by immunohistochemistry, and there was no
condensation of tumor cells around endometriotic glands,
we did not consider the presented case as a M¨ ullerian
adenosarcoma with stromal overgrowth. The lack of any
epithelial diﬀerentiation as well as any AE1/AE3 cytokeratin
immunoreactive cells excluded the diagnosis of carcinosar-
coma.
Kurihara and Oda recommended a new terminology and
classiﬁcation of non-low-grade endometrial sarcomas [19].
They divided these sarcomas morphologically into undif-
ferentiated endometrial sarcomas with nuclear uniformity
(UES-U) and undiﬀerentiated endometrial sarcomas with
nuclearpleomorphism(UES-P).TheyreportedonthatUES-
U share some molecular genetic and immunohistochemical
characteristics with low-grade ESS, but that UES-P consid-
erably diﬀers from low-grade ESS. Morphology as well as
lowandfocalestrogenandprogesteronereceptorimmunore-
activity assign our case as UES-P. However, transition to
areas with rather monotonous cells as noted in this case
may indicate a link between UES-P and UES-U by a possible
dediﬀerentiation of the latter component (Figures 1 and 2).
Since this case of ovarian UES inﬁltrated the intestines,
the possibility of a gastrointestinal stromaltumor (GIST)
must be considered. Indeed, a recent study by Irving
and Lerwill reported on gastrointestinal stromal tumors
metastatic to the ovary [20]. These authors considered
ESS in their diﬀerential considerations, too. Since most of
the tumors in that study were misdiagnosed initially, the
authors emphasized the importance of the distinction of
ESS and GIST due to signiﬁcant therapeutic and prognostic
implications. In accordance with their observations, the case
athandhadanegativeimmunophenotypeforc-kit(CD117),
which is considered a marker for GIST.
ESS metastatic from the uterus must be excluded
before giving a diagnosis of primary ovarian ESS or UES,
respectively [4]. The patient presented in this paper had
hysterectomy seven years ago. Review of the corresponding
slides did not show any evidence of a uterine stromal tumor.
In conclusion, CD10 immunoreactivity must be inter-
preted with caution since CD10 is frequently expressed in
diﬀe r e n tg y n e c o p a t h o l o g i c a la sw e l la so t h e rl e s i o n sa n d ,
thus, nonspeciﬁc. Sarcomatous overgrowth of M¨ ullerian
adenosarcoma and high-grade leiomyosarcoma is important
entities entering the diﬀerential diagnosis. Morphological
features like association with ovarian endometriosis in this
case, extensive sampling and appropriate immunohisto-
chemistry including markers for cytokeratins and myo-
genic diﬀerentiation are mandatory to arrive at the correct
diagnosis. Based on the recent literature and the ﬁndings
in this case, CD10 immunoexpression is of no diagnos-
tic value and not indicative as evidence for endometri-
oid stromal diﬀerentiation. UES should be considered
as a high-grade sarcoma with no speciﬁc diﬀerentiation
[7].
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